1. Home
  2. TOVX vs GLNG Comparison

TOVX vs GLNG Comparison

Compare TOVX & GLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOVX
  • GLNG
  • Stock Information
  • Founded
  • TOVX 2001
  • GLNG 1946
  • Country
  • TOVX United States
  • GLNG Bermuda
  • Employees
  • TOVX N/A
  • GLNG N/A
  • Industry
  • TOVX Biotechnology: Pharmaceutical Preparations
  • GLNG Marine Transportation
  • Sector
  • TOVX Health Care
  • GLNG Consumer Discretionary
  • Exchange
  • TOVX Nasdaq
  • GLNG Nasdaq
  • Market Cap
  • TOVX 3.5M
  • GLNG N/A
  • IPO Year
  • TOVX 2006
  • GLNG N/A
  • Fundamental
  • Price
  • TOVX $1.14
  • GLNG $41.33
  • Analyst Decision
  • TOVX Strong Buy
  • GLNG Strong Buy
  • Analyst Count
  • TOVX 1
  • GLNG 5
  • Target Price
  • TOVX $6.00
  • GLNG $48.30
  • AVG Volume (30 Days)
  • TOVX 96.3K
  • GLNG 1.6M
  • Earning Date
  • TOVX 11-12-2024
  • GLNG 12-31-2024
  • Dividend Yield
  • TOVX N/A
  • GLNG 2.42%
  • EPS Growth
  • TOVX N/A
  • GLNG N/A
  • EPS
  • TOVX N/A
  • GLNG 0.13
  • Revenue
  • TOVX N/A
  • GLNG $274,134,000.00
  • Revenue This Year
  • TOVX N/A
  • GLNG N/A
  • Revenue Next Year
  • TOVX N/A
  • GLNG $59.56
  • P/E Ratio
  • TOVX N/A
  • GLNG $318.34
  • Revenue Growth
  • TOVX N/A
  • GLNG N/A
  • 52 Week Low
  • TOVX $1.14
  • GLNG $19.94
  • 52 Week High
  • TOVX $17.00
  • GLNG $44.08
  • Technical
  • Relative Strength Index (RSI)
  • TOVX 36.15
  • GLNG 55.03
  • Support Level
  • TOVX $1.23
  • GLNG $40.40
  • Resistance Level
  • TOVX $1.21
  • GLNG $42.58
  • Average True Range (ATR)
  • TOVX 0.07
  • GLNG 1.51
  • MACD
  • TOVX 0.01
  • GLNG -0.21
  • Stochastic Oscillator
  • TOVX 0.00
  • GLNG 39.82

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: